Results 21 to 30 of about 986 (170)
Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction
Pharmaceutics, 2021 Late-life mild cognitive impairment and dementia represent a significant burden on healthcare systems and a unique challenge to medicine due to the currently limited treatment options.
Maria D. Auxtero +4 more
doaj +1 more source
Socio-anthropologie, 2021 This article aims at questioning the promise of cognitive optimization based on the promotion of substances classified as “nootropics”. This paper focuses on the circulation of this promise and the products that support it, as well as on contemporary ...
Félix Denis
doaj +1 more source
Awareness on nootropic herbs among dental students Herbal nootropic agents
International Journal of Research in Pharmaceutical Sciences, 2020 Nootropics herb constitutes of compounds that enhance cognitive performance by increasing mental functions memory, creativity, motivation, and attention, eventually causing individuals to be many alerts and focused. These nootropic herbs tend to enhance brain performances. To assess the awareness on nootropic herbs among dental students.
null Denesh Raj +2 more
openaire +1 more source
Vascular cognitive impairment and dementia drug-development pipeline 2025. [PDF]
Alzheimers Dement (N Y)Abstract INTRODUCTION There are currently no approved medicines for vascular cognitive impairment and dementia (VCID). METHODS We reviewed clinical trials across nine registries and included, summarized, and evaluated trials that had not yet published peer‐reviewed results by August 22, 2025.
Xu Y, Sachdev PS, Lennon MJ.
europepmc +2 more sources
Nootropics with potential to (re)build neuroarchitecture
Neural Regeneration Research, 2016 Development of effective treatments for neurodegenerative disorders is a clinical conundrum that has puzzled many researchers. Currently available drugs target symptomatic relief rather than suppressing, ceasing or repairing the devastating neural damages. For Alzheimer's disease, two classes of procognitive compounds are approved as a treatment.
Kyoko Koshibu
doaj +3 more sources
A Drug Utilization Study of Cognition Enhancers in Dementia in a Tertiary Care Hospital in Mumbai [PDF]
Journal of Clinical and Diagnostic Research, 2014 Background: Cognitive decline is one of the important factors undermining the quality of life in geriatric patients. Although the WHO has declared ‘Dementia’ as a priority health condition. Cognitive neuropharmacology is still in its infancy and there
Karan Thakkar +2 more
doaj +1 more source
Cognitive-enhancing drugs in the healthy population: Fundamental drawbacks and researcher roles
Cogent Psychology, 2015 The use of pharmacological cognitive enhancers (PCEs) in the healthy population is a controversial topic with numerous and expansive repercussions. By outlining common proponent arguments on the current PCE state of affairs, the definition of normality ...
Tsee Leng Choy
doaj +1 more source
Фармакокинетика и Фармакодинамика, 2019 Resume. The effect of subchronic administration of nootropic drugs of different structures (piracetam 200 mg/kg/day, pantocalcin 200 mg/kg/day, semax 0.6 mg/ kg/day, nooglutil 50 mg/kg/day) to mice of the outbred line 1CR on spontaneous research activity
Yu. Yu. Firstova +2 more
doaj +1 more source
Фармация и фармакология (Пятигорск), 2015 Among the contemporary medicinal remedies the derivatives of -aminobutyric acid have a special place. The present work is devoted to the remedy «Aminalon» which has a dignity of a combination of nootropic and neuroprotective actions and it has special ...
V. A. Kuchmistov, E. F. Kuchmistova
doaj +1 more source
The Psychonauts’ World of Cognitive Enhancers
Frontiers in Psychiatry, 2020 BackgroundThere is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders.
Flavia Napoletano +12 more
doaj +1 more source